ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink^® proteomics approach.

IF 2.8 3区医学 Q2 BIOCHEMICAL RESEARCH METHODS

Clinical proteomics Pub Date : 2025-01-21 DOI:10.1186/s12014-025-09527-7

Ting-Shuan Wu, Tzu-Hung Hsiao, Chung-Hsing Chen, Hsin-Ni Li, Miao-Neng Hung, Pei-Pei Jhan, Jia-Rung Tsai, Chieh-Lin Jerry Teng

{"title":"ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach.","authors":"Ting-Shuan Wu, Tzu-Hung Hsiao, Chung-Hsing Chen, Hsin-Ni Li, Miao-Neng Hung, Pei-Pei Jhan, Jia-Rung Tsai, Chieh-Lin Jerry Teng","doi":"10.1186/s12014-025-09527-7","DOIUrl":null,"url":null,"abstract":"Background: The standard \"7 + 3\" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink® platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following \"7 + 3\" induction treatment.Methods: This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to \"7 + 3\" induction therapy. We employed the Olink® Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.Results: Proteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.Conclusions: The results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the \"7 + 3\" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.","PeriodicalId":10468,"journal":{"name":"Clinical proteomics","volume":"22 1","pages":"3"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749431/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12014-025-09527-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink^® platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.

Methods: This prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink^® Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.

Results: Proteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.

Conclusions: The results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.

查看原文本刊更多论文

ARTN和CCL23预测急性髓系白血病的化疗敏感性：Olink®蛋白质组学方法

背景：标准的“7 + 3”诱导导致30%的新发急性髓性白血病（AML）患者未达到完全缓解（CR）。我们的目的是利用Olink®平台比较新诊断的新生AML患者在“7 + 3”诱导治疗后达到和未达到CR的骨髓血浆蛋白质组学特征。方法：本前瞻性研究纳入43例未经治疗的AML患者，根据患者对“7 + 3”诱导治疗的反应分为CR组（n = 29）和non-CR组（n = 14）。我们使用Olink®Explore-384炎症平台进行蛋白质组学分析，研究CR组和非CR组之间骨髓血浆蛋白水平的差异。结果：蛋白质组学分析显示，CR组骨髓血浆中ARTN和CCL23水平明显高于非CR组。免疫组化染色证实，在CR组中，ARTN （25.40% vs. 7.05%, p = 0.013）和CCL23 （24.14% vs. 14.29%, p = 0.039）强烈染色的组织样本比例更高。这些发现得到了bulk-RNA-seq的证实，结果显示ARTN mRNA表达水平显著升高(1.93 vs. -0.09；p = 0.003)和CCL23 (1.50 vs. 0.12；p = 0.021)。人类蛋白质图谱为我们的发现提供了外部支持。结论：结果提示，ARTN和CCL23可作为预测未经治疗的AML对“7 + 3”诱导反应性的生物标志物。利用酶联免疫吸附试验确定ARTN和CCL23在预测AML化疗敏感性中的作用，可能会增强未来的临床适用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical proteomics BIOCHEMICAL RESEARCH METHODS-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

17 weeks

期刊介绍： Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.